These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23611404)

  • 1. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
    Hoang T; Dahlberg SE; Schiller JH; Johnson DH
    Lung Cancer; 2013 Jul; 81(1):47-52. PubMed ID: 23611404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
    Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
    J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
    Luo J; Leaw SJ; Xu Y; Zheng D
    Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
    Scagliotti G; Brodowicz T; Shepherd FA; Zielinski C; Vansteenkiste J; Manegold C; Simms L; Fossella F; Sugarman K; Belani CP
    J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
    Sweeney CJ; Zhu J; Sandler AB; Schiller J; Belani CP; Langer C; Krook J; Harrington D; Johnson DH
    Cancer; 2001 Nov; 92(10):2639-47. PubMed ID: 11745199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
    Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
    Inal A; Kaplan MA; Kucukoner M; Urakci Z; Karakus A; Isikdogan A
    Asian Pac J Cancer Prev; 2012; 13(5):1837-40. PubMed ID: 22901132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
    Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
    Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
    Treat J; Edelman MJ; Belani CP; Socinski MA; Monberg MJ; Chen R; Obasaju CK;
    Lung Cancer; 2010 Dec; 70(3):340-6. PubMed ID: 20347506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
    Wang J; Wu N; Lv C; Yan S; Yang Y
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
    Schiller JH; Harrington D; Belani CP; Langer C; Sandler A; Krook J; Zhu J; Johnson DH;
    N Engl J Med; 2002 Jan; 346(2):92-8. PubMed ID: 11784875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
    Belani CP
    Lung Cancer; 2005 Dec; 50 Suppl 2():S3-8. PubMed ID: 16557668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
    Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L
    Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
    Natukula K; Jamil K; Pingali UR; Suresh Attili VS; Naidu Madireddy UR
    Asian Pac J Cancer Prev; 2013; 14(8):4661-6. PubMed ID: 24083721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.
    Rosati G; Rossi A; Nicolella G; Panza N
    Anticancer Res; 2000; 20(3B):2229-33. PubMed ID: 10928183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.